C/EBPβ isoform‐specific regulation of podocyte pyroptosis in lupus nephritis‐induced renal injury

Author:

Zou Huimei1234ORCID,Chen Min124,Wang Xiuhong3,Yu Jie124,Li Xiaoying5,Xie Ying124,Liu Jun6,Liu Miao7,Xu Lifen8,Zhang Qiong3,Tian Xiaoxue3,Zhang Fan124ORCID,Guo Bing124

Affiliation:

1. Department of Pathophysiology Guizhou Medical University Guiyang PR China

2. Guizhou Provincial Key Laboratory of Pathogenesis and Drug Research on Common Chronic Diseases Guizhou Medical University Guiyang PR China

3. School of Nursing, Guizhou Medical University Guiyang PR China

4. Key Laboratory of Endemic and Ethnic Diseases Ministry of Education, Guizhou Medical University Guiyang PR China

5. Department of Nephrology The First People's Hospital of Guiyang Guiyang PR China

6. Department of Rheumatology Affiliated Hospital of Guizhou Medical University Guiyang PR China

7. Department of Urinary Surgery Affiliated Hospital of Guizhou Medical University Guiyang PR China

8. Department of Pathology Affiliated Hospital of Guizhou Medical University Guiyang PR China

Abstract

AbstractAs an essential factor in the prognosis of systemic lupus erythematosus (SLE), lupus nephritis (LN) can accelerate the rate at which patients with SLE can transition to chronic kidney disease or even end‐stage renal disease. Podocytes now appear to be a possible direct target in LN in addition to being prone to collateral damage from glomerular capillary lesions induces by immune complexes and inflammatory processes. The NLRP3 inflammasome is regulated by CCAAT/enhancer‐binding protein β (C/EBPβ), which is involved in the pathogenesis of SLE. However, the role and mechanism of C/EBPβ in LN remain unclear. In this investigation, glomerular podocytes treated with LN serum and MRL/lpr mice were employed as in vivo and in vitro models of LN, respectively. In vivo, the expression of C/EBPβ isoforms was detected in kidney specimens of humans and mice with LN. Then we assessed the effect of C/EBPβ inhibition on renal structure and function by injecting RNAi adeno‐associated virus of C/EBPβ shRNA into MRL/lpr mice. In vitro, glomerular podocytes were treated with LN serum and C/EBPβ siRNA to explore the role of C/EBPβ in the activation of the AIM2 inflammasome and podocyte injury. C/EBPβ‐LAP and C/EBPβ‐LIP were significantly overexpressed in kidney tissue samples from LN patients and mice, and C/EBPβ inhibition significantly alleviated renal function damage and ameliorated renal structural deficiencies. Inflammatory pathways downstream from the AIM2 inflammasome could be suppressed by C/EBPβ knockdown. Furthermore, the upregulation of C/EBPβ‐LAP could activate the AIM2 inflammasome and podocyte pyroptosis by binding to the promoters of AIM2 and CASPASE1 to enhance their expression, and the knockdown of AIM2 or (and) caspase‐1 reversed the effects of C/EBPβ‐LAP overexpression. Interestingly, C/EBPβ‐LIP overexpression could transcriptionally inhibit IRAG and promote Ca2+ release‐mediated activation of the AIM2 inflammasome. This finding suggests that C/EBPβ is not only involved in the regulation of the expression of key proteins of the AIM2 inflammasome but also affects the polymerization of key proteins of the AIM2 inflammasome through the regulation of Ca2+ release. In conclusion, this study provides a new idea for studying the regulatory mechanism of C/EBPβ and provides a theoretical basis for the early diagnosis and treatment of LN in the future. © 2023 The Pathological Society of Great Britain and Ireland.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guizhou Province

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3